Immunotherapy does not cure most stage 4 cancers, but it has extended survival for some patients with specific cancer types

Immunotherapy works differently than traditional chemotherapy. Instead of attacking cancer cells directly, it trains your immune system to recognize and destroy them. For a small number of people with stage 4 cancer—particularly those with melanoma, certain lung cancers, and some kidney cancers—immunotherapy has produced long-term remissions that look like cures. But remission is not the same as cure. A remission means the cancer is no longer detectable, yet it can return years later.

The honest answer depends on your cancer type and how your individual tumor responds. Immunotherapy has changed outcomes for some stage 4 patients, but most people with advanced cancer will not experience a cure, even with immunotherapy. What immunotherapy can do is extend life, sometimes significantly, and improve quality of life during treatment. Understanding what the evidence actually shows—rather than what hope suggests—helps you make decisions with your oncologist based on realistic expectations.

Key Takeaways

  • Immunotherapy has produced long-term remissions in stage 4 melanoma and some advanced lung and kidney cancers, but remission is not cure and recurrence remains possible.
  • Response rates vary widely by cancer type and individual tumor characteristics; roughly 20 to 40 percent of patients with responsive cancers see meaningful benefit, while others see little or no response.
  • Immunotherapy works by activating your own immune system rather than poisoning cancer cells, which is why it can take weeks or months to show effect and why side effects differ from chemotherapy.
  • Your tumor's genetic makeup—including whether it has high mutation burden or specific genetic markers—predicts whether immunotherapy is likely to work for you.
  • Immunotherapy is often combined with chemotherapy, targeted therapy, or other immunotherapies to improve response rates in stage 4 disease.

How immunotherapy works against cancer cells

Your immune system normally patrols your body for threats, but cancer cells have evolved ways to hide from this patrol. They produce proteins that essentially tell immune cells to look away. Immunotherapy drugs block these hiding mechanisms. The main classes are checkpoint inhibitors—drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo)—which remove the "do not attack" signal that cancer cells send to immune cells called T cells.

Once that signal is blocked, your T cells can recognize the cancer as foreign and attack it. This process takes time. Unlike chemotherapy, which kills cells immediately, immunotherapy must first activate your immune system, then allow it to find and eliminate cancer cells. This is why immunotherapy often takes 8 to 12 weeks to show effect on imaging scans, and why some patients see continued improvement for months after starting treatment.

The downside is that an activated immune system can also attack healthy tissue, causing side effects called immune-related adverse events. These range from mild (rash, fatigue) to severe (inflammation of the lungs, heart, or digestive tract). Most side effects are manageable with steroids or other medications, but they require close monitoring.

Which stage 4 cancers respond best to immunotherapy

Immunotherapy has shown the clearest benefit in melanoma. Studies of checkpoint inhibitors in stage 4 melanoma show that roughly 40 to 50 percent of patients experience tumor shrinkage, and some of these remissions last for years. However, the other 50 to 60 percent see little or no benefit. For those who do respond, the question of whether remission equals cure remains open—long-term follow-up studies are still underway, but some patients have remained cancer-free for over a decade.

Non-small-cell lung cancer (NSCLC) is the second area where immunotherapy has made a measurable difference. Patients whose tumors have high PD-L1 expression (a protein that helps cancer hide from the immune system) see response rates around 40 to 50 percent. Those with lower PD-L1 expression see lower response rates, typically 20 to 30 percent. Combining immunotherapy with chemotherapy improves response rates further, to roughly 50 to 60 percent.

Renal cell carcinoma (kidney cancer) and certain other cancers show benefit, but response rates are generally lower—often in the 20 to 30 percent range. Cancers with very low mutation burden, such as prostate cancer and pancreatic cancer, have shown minimal response to immunotherapy alone, though combinations with other treatments are being studied.

The difference between remission and cure

Remission means cancer is no longer visible on scans or detectable in blood tests. It does not mean the cancer is gone at the cellular level. Microscopic cancer cells may remain dormant, and in some patients they reactivate months or years later. This is why oncologists speak of "durable remission" or "long-term remission" rather than cure—the longer a remission lasts without recurrence, the more confident they become that it may be permanent, but certainty takes time.

In melanoma, some patients have remained in remission for 10 or more years on immunotherapy, which suggests their remissions may be durable. But a patient who has been cancer-free for 5 years is not the same as a patient who has been cancer-free for 20 years. The longer the follow-up, the more confident the claim of cure. For most stage 4 cancers treated with immunotherapy, we simply do not yet have 20-year survival data.

This distinction matters for how you think about treatment. If your oncologist says immunotherapy has put your cancer into remission, that is genuinely good news—it means the treatment is working and you may have months or years of good health ahead. But it is not the same as saying the cancer will never return.

Factors that predict whether immunotherapy will work for you

Your tumor's genetic characteristics matter more than your cancer type alone. Tumors with high tumor mutational burden (TMB)—meaning they have many genetic mutations—tend to respond better to immunotherapy because those mutations make the cancer cells look more foreign to the immune system. Your oncologist can test your tumor for TMB, PD-L1 expression, and other markers that predict response.

Specific genetic mutations also matter. In lung cancer, patients with EGFR or ALK mutations often respond poorly to checkpoint inhibitors but may respond well to targeted therapies designed for those mutations. In melanoma, patients with BRAF mutations may benefit from combining immunotherapy with BRAF-targeted drugs. Your tumor's genetic profile should guide which treatment your oncologist recommends.

Your own immune system also plays a role. Patients with certain pre-existing immune conditions, or those taking immunosuppressive medications, may not respond as well to immunotherapy. Age alone does not predict response, but older patients are more likely to experience severe immune-related side effects. Your overall health, kidney and liver function, and whether you have had previous cancer treatments all influence how well immunotherapy will work and how well you will tolerate it.

Immunotherapy combined with other treatments

Immunotherapy alone produces remission in a minority of stage 4 patients. Combining it with chemotherapy, targeted therapy, or other immunotherapies often improves response rates. For example, combining two checkpoint inhibitors (such as nivolumab plus ipilimumab) produces higher response rates than either drug alone in melanoma, though it also increases the risk of severe side effects.

In lung cancer, combining immunotherapy with chemotherapy as a first-line treatment (before any other therapy) produces better survival than immunotherapy alone for many patients. Some oncologists use immunotherapy after chemotherapy, while others use them together from the start. The choice depends on your tumor type, stage, and genetic markers.

Radiation therapy can also be combined with immunotherapy. Radiation kills cancer cells and can trigger an immune response, and adding immunotherapy may amplify that response. This combination is being studied in several cancer types, particularly for patients with limited metastases (few sites of spread).

What happens if immunotherapy does not work

If your tumor does not shrink after 8 to 12 weeks of immunotherapy, or if it shrinks initially and then grows again, your oncologist will discuss other options. These might include switching to a different immunotherapy drug, adding chemotherapy or targeted therapy, trying a clinical trial testing a newer combination, or returning to chemotherapy alone.

Progression on immunotherapy does not mean you have run out of options. Many patients who do not respond to one checkpoint inhibitor respond to another. Some respond to a combination of immunotherapy plus chemotherapy after failing immunotherapy alone. Clinical trials are testing new approaches constantly, and your oncologist can help you understand which options are realistic for your specific cancer.

The decision to continue, switch, or stop treatment is personal and depends on your goals, side effects, and how you are feeling. Some patients prioritize extending life at any cost; others prioritize quality of life and may choose to stop aggressive treatment. Both are valid choices, and your oncologist should support whichever aligns with your values.

Frequently Asked Questions

Has anyone been cured of stage 4 cancer with immunotherapy?

Some patients with stage 4 melanoma have remained cancer-free for 10 or more years after immunotherapy, which suggests their remissions may be permanent. However, "cure" requires decades of follow-up data to confirm. Remission—cancer no longer detectable—is the more accurate term for what immunotherapy achieves in responsive patients.

What percentage of stage 4 cancer patients benefit from immunotherapy?

This varies by cancer type. In melanoma, roughly 40 to 50 percent of patients see tumor shrinkage. In lung cancer with high PD-L1 expression, response rates are similar. In other cancers, response rates are often 20 to 30 percent or lower. Your tumor's genetic characteristics matter more than the overall statistics.

How long does it take immunotherapy to work?

Immunotherapy typically takes 8 to 12 weeks to show effect on imaging scans. Some patients see benefit sooner; others take longer. Your oncologist will recheck scans at regular intervals—usually every 8 to 12 weeks—to see whether the cancer is shrinking, stable, or growing.

Can immunotherapy cure stage 4 cancer if chemotherapy did not work?

Yes, immunotherapy works through a different mechanism than chemotherapy, so tumors resistant to chemotherapy may respond to immunotherapy. However, if your cancer has already progressed through multiple treatments, response rates to any new treatment are generally lower. Your oncologist can discuss which options are most likely to help based on your tumor's characteristics.

What are the side effects of immunotherapy compared to chemotherapy?

Chemotherapy side effects come from poisoning rapidly dividing cells (hair loss, nausea, low blood counts). Immunotherapy side effects come from activating the immune system (rash, fatigue, inflammation of organs). Most immunotherapy side effects are manageable with steroids or other medications, but they require close monitoring and can be severe in some patients.